Pharmacologic Therapy of Non-Alcoholic Steatohepatitis

Vlad Ratziu; Shira Zelber-Sagi

doi:10.1016/j.cld.2009.07.001

Pharmacologic Therapy of Non-Alcoholic Steatohepatitis

Vlad Ratziu
, Shira Zelber-Sagi

School of Public Health

Research output: Contribution to journal › Review article › peer-review

Abstract

Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease. NASH is a recognized cause of cryptogenic cirrhosis and, increasingly, of hepatocellular carcinoma. Therefore, there is an unmet medical need for the therapy of NASH. This article discusses this therapy, with particular emphasis on pharmacologic therapy.

Original language	English
Pages (from-to)	667-688
Number of pages	22
Journal	Clinics in Liver Disease
Volume	13
Issue number	4
DOIs	https://doi.org/10.1016/j.cld.2009.07.001
State	Published - Nov 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Fibrosis
Glitazones
Hepatoprotectants
Non-alcoholic steatohepatitis
Orlistat
Sartans
Steatosis
Ursodesoxycholic acid

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.cld.2009.07.001

Cite this

@article{f36f3e71bcd34aefb4f3e2138db61fc6,

title = "Pharmacologic Therapy of Non-Alcoholic Steatohepatitis",

abstract = "Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease. NASH is a recognized cause of cryptogenic cirrhosis and, increasingly, of hepatocellular carcinoma. Therefore, there is an unmet medical need for the therapy of NASH. This article discusses this therapy, with particular emphasis on pharmacologic therapy.",

keywords = "Fibrosis, Glitazones, Hepatoprotectants, Non-alcoholic steatohepatitis, Orlistat, Sartans, Steatosis, Ursodesoxycholic acid",

author = "Vlad Ratziu and Shira Zelber-Sagi",

year = "2009",

month = nov,

doi = "10.1016/j.cld.2009.07.001",

language = "English",

volume = "13",

pages = "667--688",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Pharmacologic Therapy of Non-Alcoholic Steatohepatitis

AU - Ratziu, Vlad

AU - Zelber-Sagi, Shira

PY - 2009/11

Y1 - 2009/11

N2 - Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease. NASH is a recognized cause of cryptogenic cirrhosis and, increasingly, of hepatocellular carcinoma. Therefore, there is an unmet medical need for the therapy of NASH. This article discusses this therapy, with particular emphasis on pharmacologic therapy.

AB - Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease. NASH is a recognized cause of cryptogenic cirrhosis and, increasingly, of hepatocellular carcinoma. Therefore, there is an unmet medical need for the therapy of NASH. This article discusses this therapy, with particular emphasis on pharmacologic therapy.

KW - Fibrosis

KW - Glitazones

KW - Hepatoprotectants

KW - Non-alcoholic steatohepatitis

KW - Orlistat

KW - Sartans

KW - Steatosis

KW - Ursodesoxycholic acid

UR - https://www.scopus.com/pages/publications/70349758229

U2 - 10.1016/j.cld.2009.07.001

DO - 10.1016/j.cld.2009.07.001

M3 - Review article

C2 - 19818312

AN - SCOPUS:70349758229

SN - 1089-3261

VL - 13

SP - 667

EP - 688

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

IS - 4

ER -

Pharmacologic Therapy of Non-Alcoholic Steatohepatitis

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this